RxDoctor Payments Data

Whitney Whitaker, PA

Medical · Lexington, KYNPI 1013559848

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,090, 6.3 times the $493 reported in 2021.

$4,220in general payments, 2019–2025

Across 221 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$686
  • UCB, Inc.$596
  • Amgen$526
  • Novartis$426
  • Johnson & Johnson$350
  • GSK$288
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,12098%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,220 in reported general payments places this provider in the 80th percentile of 222 medical providers in Kentucky.

See all medical providers in Kentucky

Medicare billing

Part B allowed, 2024
$16,457
Medicare patients
86
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept71$517,743
Humira(Cf) PenAdalimumab63$452,342
RinvoqUpadacitinib46$311,021
Cosentyx Sensoready (2 Pens)Secukinumab31$245,202
Xeljanz XrTofacitinib Citrate31$166,079
Humira PenAdalimumab21$142,963
Cosentyx Sensoready PenSecukinumab15$114,468
EnbrelEtanercept12$87,916
Humira(Cf)Adalimumab13$80,280
Hydroxychloroquine Sulfate466$11,064
Leflunomide167$10,209
MethotrexateMethotrexate Sodium218$2,362
Celecoxib52$1,718
Cevimeline Hcl16$1,191
Duloxetine Hcl84$932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$686$391,30159 claims
AmgenEnbrel$526$87,91612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 medical providers in Kentucky.

Other medical in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →